Pharmacology/Pharmaceutical Industry
Consensus: nephrotoxic potential of 167 drugs in adult critically ill patients.
30 May, 2022 | 11:50h | UTCConsensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method – Drug Safety (if the link is paywalled, try this one)
Analysis/Opinion: The unintended consequences of COVID-19 vaccine policy: “why mandates, passports and restrictions may cause more harm than good”.
30 May, 2022 | 11:46h | UTC
Commentary on Twitter (thread – click for more)
📢 Our paper on COVID-19 vaccine policy has been published💉🦠
We discuss 12 unintended consequences of mandates and passports across society
& argue that pandemic vaccine policies have caused more social harm than good
Read the paper: https://t.co/TeyTki0nWI pic.twitter.com/BRJQRURbUc
— Kevin Bardosh (@KevinBardosh) May 26, 2022
Opinion: Adverse effects of acquisitions in the pharmaceutical industry.
30 May, 2022 | 10:45h | UTCAdverse effects of acquisitions in the pharmaceutical industry – Nature Medicine
Commentary on Twitter
Publicly funded research leads to the development of many new drugs, but the profits are largely reaped by big pharmaceutical companies, which can reduce competition and patients’ access to medicines, a @NatureMedicine Comment article argues. https://t.co/kUtjZa1ps1 pic.twitter.com/ccBJvpCP1t
— Nature Portfolio (@NaturePortfolio) May 26, 2022
RCT: Vitamin D does not prevent type 2 diabetes in high risk adults, trial finds.
27 May, 2022 | 12:24h | UTCNews Release: Vitamin D does not prevent type 2 diabetes in high risk adults, trial finds – BMJ
Original Study: Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population – The BMJ
Editorial: Vitamin D and risk of type 2 diabetes – The BMJ
Cohort Study: Maternal over-the-counter analgesics use during pregnancy and adverse perinatal outcomes.
27 May, 2022 | 12:22h | UTCNews Release: Painkiller advice for pregnant women should always be followed, as use is linked to newborn problems – University of Aberdeen
Related:
Paracetamol use during pregnancy — a call for precautionary action – Nature Reviews Endocrinology
Editorial: Caution needed: paracetamol use in pregnancy – Nature Reviews Endocrinology
Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds.
27 May, 2022 | 12:04h | UTCCommentary: Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds – The BMJ
Why we prescribe antibiotics for too long in the hospital setting: a systematic scoping review.
27 May, 2022 | 11:53h | UTC
Cohort Study: Analysis of antiemetic use after initiation of hormone therapy.
27 May, 2022 | 11:21h | UTCAnalysis of Antiemetic Use After Initiation of Hormone Therapy – JAMA Network Open
Cohort Study: Protection and waning of natural and hybrid immunity to SARS-CoV-2.
26 May, 2022 | 11:07h | UTCProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Commentary on Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022
Test-negative, case–control study: effectiveness of homologous and heterologous Covid-19 boosters against Omicron.
26 May, 2022 | 10:59h | UTC
M-A: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide.
26 May, 2022 | 10:13h | UTCRelated:
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Effectiveness of CoronaVac in children 3 to 5 years during the SARS-CoV-2 Omicron outbreak in Chile.
25 May, 2022 | 11:42h | UTC
Cohort Study: Analysis of neuropsychiatric diagnoses after montelukast initiation.
25 May, 2022 | 11:05h | UTCAnalysis of Neuropsychiatric Diagnoses After Montelukast Initiation – JAMA Network Open
Related:
Adverse drug reactions of montelukast in children and adults – Pharmacology Research & Perspectives
Commentary on Twitter
This cohort study of patients with asthma or allergic rhinitis found montelukast use is associated with higher odds of neuropsychiatric outcomes, including anxiety and insomnia. https://t.co/HAzcADsHZc
— JAMA Network Open (@JAMANetworkOpen) May 24, 2022
Guidelines for management of medical emergencies associated with psychotropic medications.
24 May, 2022 | 08:06h | UTC
Expert Analysis: Vascular toxicities of novel cancer therapies.
24 May, 2022 | 07:50h | UTCVascular Toxicities of Novel Cancer Therapies – American College of Cardiology
RCT: Safety and immunogenicity of heterologous boost immunization with an orally administered aerosolized Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults.
23 May, 2022 | 01:54h | UTC
Commentary on Twitter
Mix-and-match typically refers to different shots. Here's a randomized trial of shots and an oral vaccine that ameliorates the immune responsehttps://t.co/FFWHEwS37Y @LancetRespirMed pic.twitter.com/JZyvrxCalS
— Eric Topol (@EricTopol) May 21, 2022
Drugs for agitation in people with dementia: benefits and risks.
23 May, 2022 | 01:25h | UTCDrugs for agitation in people with dementia: benefits and risks – Evidently Cochrane
Original Study: Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library
Commentary on Twitter (thread – click for more)
https://twitter.com/CochraneUK/status/1527579340350935045
WHO validates 11th vaccine for COVID-19.
20 May, 2022 | 11:16h | UTCWHO validates 11th vaccine for COVID-19 – World Health Organization
Commentary on Twitter
WHO issued an emergency use listing for CONVIDECIA, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of #COVID19 vaccines validated by WHO https://t.co/QdpHiasT2p pic.twitter.com/2B54FwiNDl
— World Health Organization (WHO) (@WHO) May 19, 2022
Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO.
20 May, 2022 | 11:08h | UTCOriginal Statement: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization
Related recommendations:
M-A: Antibiotic duration for community acquired pneumonia in outpatient children in high-income countries – treatment duration of 3–5 days is equally effective and safe vs. 7–10 days.
20 May, 2022 | 11:10h | UTCRelated:
Antibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine
Commentary on Twitter
Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries – a systematic review and meta-analysis https://t.co/HxKywgCiXS
A short AB treatment of 3–5 days was equally effective and safe compared to the longer – 7–10 days— Dr. Alex 💊🩺🎮 (@DrAlexxx78) May 17, 2022
Discovery reveals blocking inflammation may lead to chronic pain.
19 May, 2022 | 11:06h | UTCNews Release: Discovery reveals blocking inflammation may lead to chronic pain – McGill University
Original Study: Acute inflammatory response via neutrophil activation protects against the development of chronic pain – Science Translational Medicine
Commentary on Twitter
Challenging medical dogma:
A very important new report suggests that non-steroidal inflammatory medications for acute pain can lead to chronic painhttps://t.co/Z8yjFFBCkK @ScienceTM https://t.co/YGjkXbvNTa pic.twitter.com/f4xVezAhau— Eric Topol (@EricTopol) May 18, 2022
Opinion | Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!
19 May, 2022 | 11:07h | UTCDoes Paxlovid help people who have been vaccinated against Covid-19? Show us the data! – STAT
Study designs for clinical trials applied to personalized medicine: a scoping review.
19 May, 2022 | 10:36h | UTCStudy designs for clinical trials applied to personalised medicine: a scoping review – BMJ Open
WHO: 2nd COVID booster for most vulnerable offers benefits.
18 May, 2022 | 11:10h | UTCWHO: 2nd COVID booster for most vulnerable offers benefits – World Health Organization
Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid).
18 May, 2022 | 11:03h | UTCCommentary: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist
Related:
Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ
Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
A living WHO guideline on drugs for covid-19 – The BMJ